Related by context. All words. (Click for frequent words.) 74 targeted radiotherapeutic 73 EP #R 73 Solazed 73 PSMA ADC 72 Zemiva TM 72 Trofex TM 72 OvaRex R 72 Solazed TM 72 eTag assays 71 Panzem R NCD 71 Trofex ™ 71 oral prodrug 71 alvespimycin 71 florbetaben 71 PEG SN# 71 Azedra 71 BrachySil TM 71 MGd 70 HDL Selective Delipidation 70 CA9 SCAN 70 fosbretabulin 70 JAK2 inhibitor 70 mertansine 70 preclinically 70 metaglidasen 70 cannabinor 70 ENMD # 69 EOquin TM 69 Chemophase 69 Azedra ™ 69 Factor VIIa 69 therapeutic monoclonal antibody 69 Phase Ib study 69 ALTROPANE 69 GAMMAGARD 69 deforolimus 69 MAGE A3 ASCI 69 Azedra TM 69 Onalta ™ 69 TG# [003] 69 CEQ# 69 Phase IIb clinical trials 69 pain palliation 69 Phase #b/#a clinical 69 tanespimycin 69 Hemopurifier ® 69 IMA# 69 Altropane 69 NPC 1C 69 Archexin 69 tafamidis 69 HuLuc# 69 THR beta agonist 69 Myocet 69 molecular imaging radiopharmaceutical 69 Aplidin 69 vidofludimus 69 Guanilib 69 NEUMUNE 69 rxRNA 68 Squalamine 68 CRLX# 68 Angiocept 68 ONCONASE R 68 Zemiva ™ 68 PET tracers 68 Combidex 68 SinuNase ™ 68 R#/MEM # 68 PDE4 inhibitor 68 CR# vcMMAE 68 radiation sensitizer 68 tubulin inhibitor 68 forodesine 68 Panzem 68 phase IIa clinical 68 QuadraSphere 68 OHR/AVR# 68 NP2 Enkephalin 68 Zybrestat 68 histone deacetylase inhibitor 68 oral picoplatin 68 PANVAC VF 68 Exherin TM 68 HDL Mimetic Peptide 68 INCB# [001] 68 ALN TTR 68 tezampanel 68 Onalta 68 PDE# inhibitors 68 including eniluracil ADH 68 PDX pralatrexate 68 trial evaluating PRX# 68 triphendiol 68 AQ4N 68 favorable pharmacokinetic profile 68 preclinical efficacy 68 IL# PE#QQR 68 Reports Preclinical Data 68 PLK1 SNALP 68 Phase 1a clinical 68 Aflibercept 67 generation URAT1 inhibitor 67 Personalized Immunotherapy 67 ZOLINZA 67 HepeX B 67 Onconase 67 RIGScan CR 67 XP# XP# 67 thetreatment 67 Plenaxis TM 67 selective androgen receptor modulator 67 YONDELIS 67 ELACYT 67 SYN# 67 Immunotherapeutic 67 multicenter Phase II 67 molecular biomarkers 67 JAK inhibitor 67 CCX# 67 ALTROPANE R 67 Cardio Vascu Grow 67 intranasal formulation 67 ARIKACE ™ 67 CMV vaccine 67 SNS# T 67 Panzem NCD 67 pharmacological chaperone 67 FOLOTYN ® 67 CCR5 mAb 67 vivo potency 67 SonoLysis 67 novel oral anticoagulant 67 Chimigen TM 67 Tarvacin TM 67 vascular disrupting agents 67 catheter occlusion 67 neratinib 67 Nektar proprietary 67 trastuzumab DM1 T DM1 67 histone deacetylase HDAC inhibitor 67 Memryte 67 Apoptone 67 Litx 67 CRMD# 67 PEGylated interferon 67 APOPTONE 67 p# biomarker 67 Virulizin ® 67 CINTREDEKIN BESUDOTOX 67 Bezielle 67 Fx #A 67 antiangiogenic agent 67 miRview mets 67 VitiGam 67 UPLYSO 67 orally administered inhibitor 67 preclinical pharmacokinetic 67 ZEVALIN ® 67 Panzem R 67 DOS# 67 TBC# 67 Curaxin 67 Initiate Clinical Trial 67 rNAPc2 67 HGS ETR2 67 OMP #M# 67 ALN VSP 67 Androxal TM 67 GEM OS2 67 NV1FGF 67 Oral NKTR 67 riociguat 67 clevidipine 67 Cloretazine 67 TKM ApoB 67 Civacir 67 systemically administered 67 targeted antifolate 67 Lixivaptan 67 pharmacodynamic effects 67 pharmacokinetic PK study 67 CD# CEA 67 phase IIb clinical 67 Solazed ™ 66 novel VDA molecule 66 hyaluronidase enzyme 66 Neuradiab 66 investigational humanized monoclonal antibody 66 Capesaris 66 radiotherapeutic 66 CB2 selective receptor agonist 66 kidney urologic 66 TKM PLK1 66 Allovectin 7 66 Hsp# inhibition 66 Iluvien ® 66 tolevamer 66 HQK 66 MAXY G# 66 AzaSite Plus 66 pharmacodynamic PD 66 Phase IIb III 66 isoform selective 66 nanopharmaceutical 66 Tyrima 66 next generation URAT1 66 genomic biomarker 66 selective modulator 66 OncoVEX 66 SNT MC# 66 TOLAMBA 66 Pimavanserin 66 Cloretazine ® 66 registrational 66 Phase #/#a trial 66 IMC #B 66 OncoVEX GM CSF 66 PI3K/Akt pathway inhibitor 66 OMNARIS HFA 66 hoFH 66 ATIR 66 PSN# [002] 66 EndoTAGTM 1 66 Triapine R 66 PEG uricase 66 busulfan 66 depsipeptide 66 gefitinib Iressa 66 Symadex 66 Allovectin 7 R 66 oral ridaforolimus 66 HGS ETR1 66 tezampanel NGX# 66 Nanobody 66 pharmacodynamic markers 66 Mipomersen 66 Nasulin ™ 66 Generx ™ 66 Alfacell proprietary ribonuclease 66 Generx TM 66 biomarker assays 66 SUTENT ® 66 MGN# 66 MYDICAR 66 BRIM2 66 EndoTAG TM -1 66 investigational hepatitis C 66 DAVANAT 66 evaluating tivozanib 66 Traficet EN 66 GED aPC 66 Xanafide 66 p# inhibitor 66 liposomal formulation 66 BHT DNA 66 indibulin 66 Breast Cancer Assay 66 NeoLipid R 66 Cleviprex TM clevidipine 66 molecular imaging radiopharmaceuticals 66 differentiate squamous 66 CCR9 antagonist 66 non nucleoside 66 antiangiogenic activity 66 Xcytrin R 66 Collategene 66 PORxin TM 66 delipidation 66 DPX Survivac 66 initiate Phase 1b 66 SuperAntibody 66 Phase 2a clinical trials 66 potent antiproliferative 66 HuMax EGFr 66 IRX 2 66 CYT# potent vascular disrupting 66 phase IIb trial 66 Phase Ib II 66 ALN PCS 66 Novolimus 66 drug GLPG# 65 PNP inhibitor 65 StemEx R 65 cMET 65 novel peptide 65 telomerase inhibitor drug 65 Spiegelmer ® 65 lumiliximab 65 optimal dosing regimens 65 Adenoscan R 65 ophthalmology dermatology cardiovascular disease 65 eprotirome 65 MKC# MKC# PP 65 PHX# 65 novel anticancer 65 Onalta TM 65 Marqibo TM 65 ImmuKnow R 65 TLK# 65 ospemifene 65 Romidepsin 65 GVAX ® 65 rBChE 65 GLP toxicology studies 65 MCSP respectively 65 RIGScan 65 sitaxsentan 65 investigational therapies 65 lexidronam injection 65 KRN# 65 bardoxolone methyl 65 intranasal insulin product 65 PrevOnco 65 TELINTRA 65 alemtuzumab MS 65 lintuzumab 65 Zenvia ™ 65 Canvaxin TM 65 systemic RNAi therapeutic 65 PD2i 65 BLA filing 65 viral kinetics 65 OvaRex ® MAb 65 inhaled AAT 65 NTDDS 65 ZYBRESTAT fosbretabulin 65 Xcellerated T Cells 65 Evoltra ® 65 antiangiogenic agents 65 aldehyde dehydrogenase ALDH2 deficiency 65 Phase Ib clinical trials 65 accumulate preferentially 65 PRT# 65 Safinamide 65 herpetic keratitis 65 dacetuzumab 65 lintuzumab SGN 65 atacicept 65 miRview ™ squamous 65 lorvotuzumab mertansine 65 rALLy trial 65 seliciclib CYC# 65 IIa trial 65 reslizumab 65 AEG# 65 targeting CD# 65 pharmacodynamic properties 65 Tarmogen 65 refractory chronic lymphocytic 65 VeraTag 65 OncoGel 65 EndoTAG TM 65 Hedgehog antagonist 65 Phase #b/#a trial 65 Cannabinor 65 personalized immunotherapy 65 refractory prostate cancer 65 ESBA# 65 ixabepilone 65 NeuroSTAT ® 65 HuMax TAC 65 Vascugel 65 BRAF inhibitors 65 Excellagen 65 HepeX B TM 65 candidate CRLX# 65 DermaVir Patch 65 Hedgehog inhibitor 65 romidepsin novel 65 trastuzumab DM1 65 AERx iDMS 65 Degarelix 65 relapsed MM 65 EECP ® therapy 65 Fibrillex TM 65 Genz # 65 GLPG# 65 ongoing Phase 1b 65 DCVax R 65 initiated Phase 1b 65 Kahalalide F 65 Telatinib 65 EmbraceAC 65 Beta catenin pathway 65 OXi# 65 Urocortin 2 65 Vitaxin 65 NEUGENE antisense 65 Phase 2b Clinical Trial 65 inhibit metastasis 65 aurora kinase 65 human IgG1 monoclonal 65 demonstrated antitumor activity 65 Tectin TM 65 uricase 65 urocortin 2 65 novel histone deacetylase 65 Neo Kidney Augment 65 miRNA biomarkers 65 elotuzumab 65 PLX cells 65 GTC recombinant human 65 LymphoStat B TM 65 VALSTAR 65 ruxolitinib 65 PrevOnco ™ 65 teduglutide 65 ganetespib 65 Biomerk Tumorgrafts 65 potency selectivity 65 BiTE 65 mGluR2 NAM 65 alemtuzumab Campath 65 opioid induced bowel dysfunction 65 hypoxia activated prodrug 65 R roscovitine 65 plasma kallikrein inhibitor 65 CBLC# 65 budesonide foam 65 Proellex TM 65 HCV polymerase 65 novel therapeutic antibodies 65 generation purine nucleoside 65 incyclinide 65 LEUKINE 65 Phase III Pivotal 65 EVIZON TM 65 OMS# 65 metastatic neuroendocrine tumors 65 XmAb 65 biomarker identification 65 huC# DM4 64 HuMax 64 Gliadel Wafer 64 interleukin IL -# 64 LHRH receptor positive 64 ALK inhibitor 64 NADiA ProsVue 64 oral methylnaltrexone 64 RhuDex ® 64 vinca alkaloid 64 NeoLipid TM 64 HERmark assay 64 MAP# 64 INTERCEPT platelets 64 rALLy clinical trial 64 BEMA TM Fentanyl 64 JAK inhibitors 64 PRESEPT study 64 MEK inhibitor 64 Aurexis 64 mTOR inhibition 64 Neo Kidney Augment ™ 64 cediranib 64 TACI Ig 64 Phase Ib clinical 64 Exelixis compounds 64 cancer immunotherapies 64 RNAi therapeutic targeting 64 R sorafenib tablets 64 Prednisporin TM 64 Florbetapir 64 Perflubutane Polymer Microspheres 64 TRO# 64 RAV# 64 ZFP Therapeutics 64 GRN# 64 biomarker assay 64 BrachySil ™ 64 TransVax tm 64 ALGRX 64 Initiates Enrollment 64 immatics 64 Linjeta TM 64 myelofibrosis polycythemia vera 64 galiximab 64 Aviptadil 64 NEUGENE 64 ASONEP 64 sorafenib tablets 64 AAG geldanamycin analog 64 TOCOSOL Camptothecin 64 HCV protease inhibitors 64 CG# [003] 64 Kamada AAT 64 nonclinical studies 64 MKC# MT 64 Sphingomab TM 64 epothilone 64 multicenter clinical trials 64 NNR Therapeutics 64 factor VIIa 64 Fodosine 64 imetelstat 64 lead molecular radiotherapeutic 64 tumorigenicity 64 DEEP AF 64 OvaRex 64 HCV protease inhibitor 64 INS# [001] 64 XYOTAX TM 64 intravenous acetaminophen 64 ganaxolone 64 IMPDH inhibitor 64 XL# XL# 64 ALN TTR# 64 Phase #b/#a 64 Ophena TM 64 Pertuzumab 64 cellular immunotherapy 64 PET tracer 64 topically applied SEPA 64 predictive toxicology 64 thymalfasin 64 acetonide FA 64 mitogen activated ERK kinase 64 BiTE antibody 64 Zemiva 64 Specifid 64 MOZOBIL 64 microRNA biomarkers 64 oncolytic virus therapies 64 NADiA 64 ARC# [002] 64 CorVue 64 investigational pan BCR 64 ostarine 64 Anavex #-# 64 GRNVAC1 64 vascular disrupting agent 64 orally dosed 64 XmAb# 64 Hsp# Inhibitor 64 diagnostic biomarker 64 inhaled liposomal ciprofloxacin 64 torezolid phosphate 64 Vaxfectin R adjuvant 64 KNS # 64 farletuzumab 64 Spiegelmers 64 Vaxfectin TM 64 MEND CABG II 64 eniluracil 64 Synavive ™ 64 NuroPro R 64 Allovectin 7 ® 64 ORE# 64 RGB # 64 delafloxacin 64 Urocidin 64 Plicera 64 Homspera TM 64 vorinostat 64 LibiGel ® 64 Presents Preclinical Data 64 BNC# 64 Excellarate 64 Gamunex C 64 candidates Azedra TM 64 IMiDs R 64 ADVEXIN therapy 64 pharmacodynamic parameters 64 Davanat 64 PFO migraine 64 file INDs 64 Phase IIa trials 64 YONDELIS R 64 VITAL Trial 64 LEP ETU 64 orally inhaled migraine 64 bortezomib Velcade 64 Annexin V 64 HuCNS SC ® 64 NB S# strontium malonate 64 aerosolized surfactant 64 MORAb 64 STRIDE PD 64 Thalomid ® 64 docetaxel Taxotere ® 64 fusion enhancers 64 Septin9 biomarker 64 samalizumab 64 WavSTAT 64 Urocidin TM 64 Vilazodone 64 Bioral ® 64 ORENCIA R 64 TELINTRA R 64 #I TM# 64 CA4P 64 Diabetic Macular Edema DME 64 proteomic biomarkers 64 obatoclax 64 Opterone 64 HuCAL antibodies 64 Tß4 64 Soliris TM eculizumab 64 IND submission 64 Quinamed 64 K ras mutations 64 candidate REP# 64 Phase 1b trial 64 varespladib 64 Aganocide 64 Initiates Clinical 64 phase IIa 64 Lisofylline 64 bafetinib 64 epigenetic therapies 64 radiolabeled 64 GW# [003] 64 Potelligent Technology 64 ularitide 64 VIAject R 64 peptidomimetic 64 initiated Phase Ib 64 pharmacokinetic equivalence 64 midstage clinical 64 QTinno TM 64 PXD# 64 verteporfin 64 OncoVex 64 potent suppressor 64 antisense inhibitors 64 Toraymyxin TM 64 GRNCM1 64 Bendavia 64 Dacogen injection 64 EGS# 64 PD LID 64 histone deacetylase HDAC 64 Dendreon investigational 64 omega interferon 64 KSP inhibitor 64 HDAC Inhibitor 64 EOquin 64 successfully commercialize Iluvien 64 paclitaxel poliglumex 64 NSCLC tumors 64 non nucleoside HCV 64 ATPace TM 64 PF # [002] 64 Octreolin 64 pan HDAC inhibitor 64 Soliris eculizumab 64 rhITF 64 molecular chaperone regulation 64 Kosan dependence 64 Amplimexon 64 PRECISE trial 64 Cardio3KG 64 huN# DM1 64 JAK2 Inhibitor 64 E2F Decoy 64 pharmacokinetic PK 64 phase Ib 64 Alzhemed TM 64 Shigamabs ® 64 OXIGON TM 64 MYDICAR ® 64 novel peptides 64 Protexia ® 64 ADAGIO study 64 kinase profiling 64 molecular diagnostic assay 64 PROSTASCINT R 64 CINQUIL 64 sargramostim 64 Azedra TM Onalta TM 64 Daniel Junius 64 Golimumab 64 volociximab 64 Hepatocellular Carcinoma HCC 64 HCD# [002] 64 Fibrin Pad 64 investigational monoclonal antibody 63 histamine dihydrochloride 63 siRNA therapeutic 63 Angiolix 63 Celator 63 GnRH antagonist 63 entinostat 63 anti CD# antibodies 63 Cloretazine R 63 molecular chaperone amplification 63 HuMax CD4 63 MT#/MEDI-# 63 CYC# 63 antibody MAb 63 PRX# 63 proton MR spectroscopy 63 defensin mimetic antibiotic 63 systemic immunosuppressive drugs 63 Tarceva TM 63 Phase IIIb clinical 63 Anti VEGF 63 visit www.genenews.com 63 phase IIb study 63 ILUVIEN ® 63 PEGPH# 63 MAXY VII 63 vivo preclinical 63 overactive bladder AA# 63 Pancreate 63 Vidaza azacitidine 63 Ceflatonin 63 Dalbavancin 63 antibody MT# 63 Sym# 63 oral deforolimus 63 aerosolized KL4 surfactant 63 BioNumerik 63 Nicole Onetto MD 63 Cx# [002] 63 Elocalcitol 63 Tomophase 63 haematologic 63 NPSP# 63 TLR antagonists 63 JAK#/JAK# inhibitor CYT# 63 virus HCV protease inhibitor 63 Hexvix 63 Hedgehog Pathway Inhibitor 63 candidate TNFerade biologic 63 ulimorelin 63 IAP inhibitor 63 Presents Preclinical 63 vitro ADME 63 intravesical infusion therapy 63 chronic myocardial ischemia 63 iroxanadine 63 P2V TM 63 TPI ASM8 63 VEGFR2 inhibitor 63 radiolabeled TM# 63 tranilast 63 Anturol TM 63 pharmacodynamic profiles 63 Electronic Brachytherapy 63 orally bioavailable 63 hA# 63 Virulizin R 63 Campath ® 63 Fabry Disease 63 AZILECT ® 63 MelaFind R 63 Varespladib 63 serum biomarkers 63 Lisofylline LSF 63 oral antiviral 63 radiation dosimetry 63 tiapamil 63 Completes Patient Enrollment 63 SAR# [004] 63 ThermoDox R 63 Corgentin 63 leading oral taxane 63 FluCide 63 malignant ascites 63 null responder 63 Clolar ® 63 gemcitabine Gemzar ® 63 glucokinase activator 63 haematological cancers 63 Metastatic Melanoma 63 Bayer HealthCare Onyx Pharmaceuticals 63 Aethlon Hemopurifier R 63 Pharmacodynamic 63 DURIN TM 63 VitiGam TM 63 PI3K/mTOR 63 chemosensitivity 63 OMP #R# 63 Triolex 63 telaprevir VX 63 Targretin capsules 63 Prodarsan R 63 ProstaScint 63 therapeutic peptide 63 Begins Dosing 63 CIMZIA ™ 63 Xerecept 63 pralatrexate 63 pexiganan 63 tosedostat 63 immuno therapeutic 63 metabolite identification 63 Silodosin 63 CARE HF 63 confirmatory clinical 63 Anticalins ® 63 Tumour Vascular Disrupting Agent 63 adipiplon 63 Sphingomab 63 NOD SCID mice 63 antiproliferative effects 63 isatoribine 63 Pharmacokinetic studies 63 Insegia 63 teriflunomide 63 Sulonex TM 63 Annamycin 63 A3 adenosine receptor 63 Zemplar Capsules 63 efaproxiral 63 ATL# [002] 63 oral talactoferrin 63 axitinib 63 MyVax ® 63 TOCOSOL Paclitaxel 63 Trastuzumab DM1 63 Asentar 63 plasma pharmacokinetics 63 SMT C# 63 systemic anaplastic large 63 budesonide MMX Phase III 63 cartilage regeneration 63 polysaccharide polymer 63 small molecule activators 63 rhFVIIa 63 perfusion imaging 63 Georges Gemayel 63 antiangiogenic therapy 63 Augment TM 63 Muraglitazar 63 Optiquel ™ 63 synthetic retinoid 63 immunomodulatory properties 63 taxane resistant 63 refractory colorectal cancer 63 immuno inflammatory 63 ZACTIMA 63 Alocrest 63 Ophena 63 Surfaxin LS 63 ProSavin 63 phosphatidylserine PS targeting 63 lung pancreatic 63 Neo Urinary Conduit 63 Vascular Wrap 63 cleavable linker 63 Troxatyl 63 humanized monoclonal antibodies 63 SinuNase TM 63 Pivotal Phase III 63 Activity Assay 63 nucleoside analog 63 Androxal ® 63 potently inhibit 63 AMD# [003] 63 Dacogen decitabine 63 Omacetaxine 63 molecular biomarker 63 kinase inhibition 63 Carfilzomib 63 magnetic resonance angiography MRA 63 Adnectin 63 Prodarsan ® 63 Pervasis 63 Anticalins R 63 VNP#M 63 JAK1 63 CellSearch System 63 Antiangiogenic 63 PhG alpha 1 63 biostatistical analysis 63 #ME# 63 Anticalin ® 63 ATL# [001] 63 BEMA Granisetron 63 multimodality imaging 63 receptor tyrosine kinase inhibitor 63 pharmacogenomic translational research 63 ENRICH trial 63 Panzem ® 63 interferon gamma 1b 63 pomalidomide 63 Abiraterone acetate 63 Stedivaze 63 TÎ ² 4 63 blood clot dissolver 63 DXL# 63 diagnostic molecular imaging 63 INSPIRE Trial Phase III 63 immunomodulatory therapy 63 esophageal candidiasis 63 SNALP technology 63 PresbyLens ® 63 Cloretazine R VNP#M 63 Corus CAD 63 GMX# 63 liposomal doxorubicin 63 immune modulating 63 QTinno 63 glufosfamide 63 immunotherapeutic vaccine 63 PEARL SC 63 vapreotide acetate 63 endocrine therapies 63 #F AV 63 Harry Palmin President 63 immuno modulatory 63 Spheramine 63 epoetin alpha 63 LEAPS TM 63 ApoB SNALP 63 BRIM3 63 HGS# 63 proteasome inhibitor 63 TRIOLEX HE# APOPTONE HE# 63 masitinib 63 CTAP# Capsules 63 Aeolus Pharmaceuticals Announces 63 Aurora kinase inhibitor 63 Daclizumab 63 NP2 63 chimeric monoclonal antibody 63 INT# [002] 63 Zavesca r 63 ENDEAVOR IV 63 haematologic malignancies 63 AFRS TM 63 IAP inhibitors 63 ABL inhibitor 63 compound AEZS 63 TRIST study 63 vinorelbine tartrate 63 Maxy G# 63 XOMA 3AB 63 pertuzumab 63 GATTEX ® 63 HTS assay 63 Myocardial Perfusion Imaging 63 velafermin belinostat 63 MorphoSys proprietary 63 LEVADEX ™ 63 Radilex 63 TASKi3 63 ReN# 63 AeroLEF TM 63 Phase III Clinical Trial 63 Manja Bouman CEO 63 Genasense ® 63 Dyloject TM 63 Lenocta 63 mGlu2 3 63 Aurora Kinase 63 IMiDs ® 63 IGF 1R inhibitor 63 Hemopurifier 63 biliary tract cancer 63 JAK2 inhibitors 63 Phase IIB 63 Initiates Clinical Trial 63 vosaroxin 62 therapeutic radiopharmaceuticals 62 XL# anticancer compounds 62 Phase IIa trial 62 MyVax R 62 delivers fluocinolone acetonide FA 62 recombinant polyclonal antibody 62 humanized therapeutic 62 anti CD3 62 Excellarate TM 62 Atiprimod 62 Adrian Hobden Ph.D. 62 PREOS 62 Poly ICLC 62 humanised monoclonal antibody 62 metastatic sarcomas 62 Phase III ADT 62 intravenous methylnaltrexone 62 Selective Electrochemical Tumor Ablation 62 intradermal injections 62 CardioPET 62 novel emulsion formulation 62 bardoxolone 62 vivo fluorescence imaging 62 Ataluren 62 SERMs 62 Cethrin 62 zanolimumab 62 novel immunotherapeutic 62 anticancer compound 62 HGS ETR1 mapatumumab 62 Matrix Phase 2b 62 arterial thrombosis 62 Saforis 62 rhIGF-I/rhIGFBP-3 62 BioDisc 62 PROSTVAC VF 62 Ecallantide 62 DNA methylation markers 62 relapsed multiple myeloma 62 Phenoptin 62 Meets Primary Endpoint 62 Sudhir Agrawal D.Phil 62 anti fibrotic